Finance & Investment

California Resources Corporation is swapping old debt for new. We dive into how this $550M move bolsters its balance sheet and fuels its carbon-cutting ambitions.

SOLVE's new cohort analysis tool isn't just tech; it's a strategic move in the AI arms race to close the execution gap in fixed income investing.

Adial Pharmaceuticals pivots from addiction to inflammation, securing $32M and poaching Azora's leadership to drive its new ulcerative colitis drug, AT177.

With its new Stripe-powered payment feature, Precoro aims to end the manual chaos plaguing mid-market finance teams by unifying the entire procure-to-pay loop.

Ninepoint's new ETF offers Canadians a ticket to the SpaceX growth story, but its leveraged, high-income structure demands a closer look at the risks.

Aviso's landmark deal with Broadridge is more than a tech upgrade; it's a strategic overhaul signaling an industry-wide shift to open, agile platforms.

With a major debt financing, French biotech Inventiva is funded through a pivotal Phase 3 trial for its MASH drug, highlighting a strategic shift in biotech funding.

A local firm wins its community's top award for the eighth time. We look past the trophy to analyze the blend of fiduciary focus and national growth driving its success.

A new firm, born from Blackstone's ranks, has launched with a $1.5 billion war chest to tackle a massive gap in corporate finance. But can it truly reshape the market?

Great Estate Blockchain divests its main revenue source after a flawed deal structure implodes, leaving the penny-stock firm seeking a new identity.

NeoGenomics is raising $275M via convertible notes. We dissect the sophisticated financing, from dilution-hedging calls to the market impact for investors.

The financial giant sets its 2027 Investor Day. Beyond the date, it's a signal of intent for navigating a fractured world with a $4.9T balance sheet.

Adaptive Biotechnologies' new debt offering is more than a financial tune-up; it's a calculated move to sever a costly royalty deal and arm its star MRD division for a separate future.

The sports betting ETF is ditching its passive index. This strategic pivot is more than a fund management change; it’s a bet on active management.

Targeting advisor frustration, Wallace Finance launches a unified AI platform for wealth managers, aiming to cut costs and democratize advanced investing.

UWM Holdings publicly blasts the Two Harbors board, alleging bad faith and obstruction while urging shareholders to reject a rival merger in a proxy showdown.

Northann Corp. is back in the NYSE's good graces, but a closer look reveals a risky path. Can its innovative 3D printing tech overcome financial headwinds?

After a $40 billion market collapse, venture capital is back with a new playbook. Anterra Capital’s new fund signals a shift from hype to real-world AI.

Pacer ETFs slashes fees and expands its Swan SOS series, intensifying competition in the $92 billion buffer ETF market for risk-conscious investors.

With unsolicited offers for AI infrastructure on the table and its aviation platform soaring, Volato is at a strategic crossroads. Can it leverage its niche success for a bigger prize?